Microbiota-Gut-Brain Axis and Antidepressant Treatment
- PMID: 37962812
- DOI: 10.1007/7854_2023_449
Microbiota-Gut-Brain Axis and Antidepressant Treatment
Abstract
In the treatment of depressive disorders, conventional antidepressant therapy has been the mainstay of clinical management, along with well-established nonpharmacological interventions such as various kinds of psychotherapy. Over the last 2 decades, there has been considerable interest in the role of the gastrointestinal system and its microbiota on brain function, behavior, and mental health. Components of what is referred to as the microbiota-gut-brain axis have been uncovered, and further research has elicited functional capabilities such as "gut-brain modules." Some studies have found associations with compositional alterations of gut microbiota in patients with depressive disorders and individuals experiencing symptoms of depression. Regarding the pathogenesis and neurobiology of depression itself, there appears to be a multifactorial contribution, in addition to the theories involving deficits in catecholaminergic and monoamine neurotransmission. Interestingly, there is evidence to suggest that antidepressants may play a role in modulating the gut microbiota, thereby possibly having an impact on the microbiota-gut-brain axis in this manner. The development of prebiotics, probiotics, and synbiotics has led to studies investigating not only their impact on the microbiota but also their therapeutic value in mental health. These psychobiotics have the potential to be used as therapeutic adjuncts in the treatment of depression. Regarding future directions, and in an attempt to further understand the role of the microbiota-gut-brain axis in depression, more studies such as those involving fecal microbiota transplantation will be required. In addition to recent findings, it is also suggested that more research will have to be undertaken to elicit whether specific strains of gut organisms are linked to depression. In terms of further investigation of the therapeutic potential of prebiotics, probiotics, and synbiotics as adjuncts to antidepressant treatment, we also expect there to be more research targeting specific microorganisms, as well as a strong focus on the effects of specific prebiotic fibers from an individualized (personalized) point of view.
Keywords: Antidepressants; Depression; Fecal microbiota transplantation; Gut microbiota; Microbiota-gut-brain axis; Prebiotics; Probiotics; Psychobiotics; Synbiotics.
© 2023. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Similar articles
-
Emerging role of Gut-microbiota-brain axis in depression and therapeutic implication.Prog Neuropsychopharmacol Biol Psychiatry. 2021 Mar 2;106:110138. doi: 10.1016/j.pnpbp.2020.110138. Epub 2020 Oct 16. Prog Neuropsychopharmacol Biol Psychiatry. 2021. PMID: 33075447 Review.
-
The Role of Probiotics and Their Metabolites in the Treatment of Depression.Molecules. 2023 Apr 4;28(7):3213. doi: 10.3390/molecules28073213. Molecules. 2023. PMID: 37049975 Free PMC article. Review.
-
Probiotics, Prebiotics and Postbiotics on Mitigation of Depression Symptoms: Modulation of the Brain-Gut-Microbiome Axis.Biomolecules. 2021 Jul 7;11(7):1000. doi: 10.3390/biom11071000. Biomolecules. 2021. PMID: 34356624 Free PMC article. Review.
-
Can psychobiotics "mood" ify gut? An update systematic review of randomized controlled trials in healthy and clinical subjects, on anti-depressant effects of probiotics, prebiotics, and synbiotics.Clin Nutr. 2020 May;39(5):1395-1410. doi: 10.1016/j.clnu.2019.06.004. Epub 2019 Jun 12. Clin Nutr. 2020. PMID: 31307840
-
Exploring the gut-brain Axis: Potential therapeutic impact of Psychobiotics on mental health.Prog Neuropsychopharmacol Biol Psychiatry. 2024 Aug 30;134:111073. doi: 10.1016/j.pnpbp.2024.111073. Epub 2024 Jun 22. Prog Neuropsychopharmacol Biol Psychiatry. 2024. PMID: 38914414 Review.
Cited by
-
Ghrelin, Neuroinflammation, Oxidative Stress, and Mood Disorders: What Are the Connections?Curr Neuropharmacol. 2025;23(2):172-186. doi: 10.2174/1570159X22999240722095039. Curr Neuropharmacol. 2025. PMID: 39041263 Free PMC article. Review.
-
Microbiota and Postmenopause: The resilience of intestinal bacteria in the face of female hormonal aging.PLoS One. 2025 Jun 18;20(6):e0324712. doi: 10.1371/journal.pone.0324712. eCollection 2025. PLoS One. 2025. PMID: 40531943 Free PMC article.
References
-
- Abildgaard A, Elfving B, Hokland M, Wegener G, Lund S (2017) Probiotic treatment reduces depressive-like behaviour in rats independently of diet. Psychoneuroendocrinology 79:40–48. https://doi.org/10.1016/j.psyneuen.2017.02.014 - DOI - PubMed
-
- Ait Chait Y, Mottawea W, Tompkins TA, Hammami R (2020) Unravelling the antimicrobial action of antidepressants on gut commensal microbes. Sci Rep 10(1). https://doi.org/10.1038/s41598-020-74934-9
-
- Alcock J, Maley CC, Aktipis CA (2014) Is eating behavior manipulated by the gastrointestinal microbiota? Evolutionary pressures and potential mechanisms. Bioessays 36(10):940–949. https://doi.org/10.1002/bies.201400071 - DOI - PubMed - PMC
-
- Alfaifi AA, Althemery AU (2022) Sociodemographic characteristics and health-related quality of life of individuals undergoing antidepressant therapy. Sci Rep 12(1). https://doi.org/10.1038/s41598-022-22164-6
-
- Allen AP, Naughton M, Dowling J, Walsh A, Ismail F, Shorten G, Scott L, McLoughlin DM, Cryan JF, Dinan TG, Clarke G (2015) Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: a comparison of ketamine and ECT. J Affect Disord 186:306–311. https://doi.org/10.1016/j.jad.2015.06.033 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical